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IMMUNOBIOLOGY
Wiskott-Aldrich syndrome protein deficiency in B cells results in impaired
peripheral homeostasis
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Gerben Bouma,4 Adrian J. Thrasher,4 Facundo D. Batista,3 and David J. Rawlings1,5
1Department of Pediatrics, Seattle Children’s Hospital Research Institute, WA; 2Center for Cellular and Molecular Therapy, GIGA-R, University of Liege, Liege,
Belgium; 3Lymphocyte Interaction Laboratory, Cancer Research UK London Research Institute, London, United Kingdom; 4Centre for Immunodeficiency,
University College London and Great Ormond Street Hospital for Children National Health Service (NHS) Trust, London, United Kingdom; and 5Department of
Immunology, University of Washington School of Medicine, Seattle
To more precisely identify the B-cell pheno-
type in Wiskott-Aldrich syndrome (WAS), we
used 3 distinct murine in vivo models to
define the cell intrinsic requirements for
WAS protein (WASp) in central versus pe-
ripheral B-cell development. Whereas WASp
is dispensable for early bone marrow
B-cell development, WASp deficiency re-
sults in a marked reduction in each of the
major mature peripheral B-cell subsets,
exerting the greatest impact on marginal
zone and B1a B cells. Using in vivo bro-
modeoxyuridine labeling and in vitro func-
tional assays, we show that these deficits
reflect altered peripheral homeostasis,
partially resulting from an impairment in
integrin function, rather than a develop-
mental defect. Consistent with these ob-
servations, we also show that: (1) WASp
expression levels increase with cell matu-
rity, peaking in those subsets exhibiting
the greatest sensitivity to WASp defi-
ciency; (2) WASp murine B cells exhibit
a marked selective advantage beginning
at the late transitional B-cell stage; and
(3) a similar in vivo selective advantage is
manifest by mature WASp human B cells.
Together, our data provide a better under-
standing of the clinical phenotype of WAS
and suggest that gene therapy might be a
useful approach to rescue altered B-cell
homeostasis in this disease. (Blood. 2008;
112:4158-4169)
Introduction
Wiskott-Aldrich syndrome (WAS) is an X-linked immunodefi-
ciency disorder characterized by recurrent infections, microthrom-
bocytopenia, and eczema. In addition, WAS is associated with an
increased incidence of autoimmune disease and hematologic
malignancies, especially B-cell lymphomas.1 Affected patients are
susceptible to bacterial, viral, and fungal infections, secondary to
defects in both cellular and humoral immunity. Lymphopenia is a
common finding in WAS patients from infancy on, mainly because
of reduced numbers of T cells, whereas B cells are normal or
moderately decreased.2,3 Antibody responses are adequate to some
antigens and insufficient to others. In particular, WAS patients fail
to respond to polysaccharide antigens and are highly susceptible to
infections with Streptococcus pneumoniae.4
The affected gene, WASP, encodes a multidomain protein,
WASp, which is exclusively expressed in hematopoietic cells and is
the founding member of a family of proteins involved in the
transduction of signals to the actin cytoskeleton.5 The actin
cytoskeleton plays a crucial role in cell adhesion and migration,
antigen receptor surface assembly and turnover, and formation of
the T-cell immunologic synapse on cell stimulation. Each of these
pathways can be affected in WAS and contribute to the clinical
phenotype. Several studies have demonstrated defective macro-
phage and DC migration and adhesion,4 and more recent studies
also suggest impaired trafficking of T and B cells as well as
neutrophils.6-9 Both human and murine WASp/ T cells exhibit
defective actin polymerization, impaired T-cell receptor cap-
ping,10-13 reduced ability to produce interleukin-2, and decreased
proliferation in response to anti-CD3 stimulation in vitro.14
Studies investigating B-cell function in both human and murine
WAS have been more limited in scope and have led to various
results and interpretations. Study of Epstein-Barr virus–
transformed B-cell lines derived from WAS patients showed
defective actin polymerization.15 Ca-flux upon B-cell receptor
(BCR) stimulation of human B cells has been reported to be
normal16 or reduced.17 In WASp/ mice, the proliferative response
to BCR engagement was either slightly reduced13 or normal.12,13
The latter study also showed normal capping of B cells in response
to BCR stimulation. Westerberg et al demonstrated impaired
polarization, spreading, homotypic aggregation, and microvilli
formation in response to CD40 stimulation, and defective migra-
tion to CXCL13 in WASp/ primary murine B cells.8,18 In
addition, both WAS patients and WASp/ mice exhibit a marked
reduction in the number of splenic marginal zone (MZ) B cells.8,19
These findings are consistent with the lack of antibody responses to
pneumococcal polysaccharides in humans2 and decreased antibody
response to TI immunization with dextran in mice.8
In an effort to better understand the relative contributions of the
B-cell lineage to the immunodeficiency of WAS, we performed a
detailed analysis of each of the major B-cell developmental subsets
in WASp/ animals. We also used 3 independent in vivo models to
precisely characterize the requirement for WASp in the central
versus peripheral B-cell compartments. Our results demonstrate
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specific, B cell–intrinsic defects in cell numbers within each of the
mature B-cell developmental subsets. Further, using a combination
of in vitro functional assays and in vivo labeling studies, our data
demonstrate that these changes reflect altered B lymphoid homeosta-
sis rather than a developmental defect. Finally, we show that
WASp-expressing B cells exhibit a strong selective advantage over
WASp-deficient B cells in both humans and mice.
Methods
Animal studies
Six- to 8-week-old C57BL/6, MT and WASp/ (F10 on a C57BL/6
background) mice were maintained in the SPF animal facility at Children’s
Hospital (Seattle, WA) and handled according to Institutional Animal Care
and Use Committee-approved protocols. Bone marrow (BM) was harvested
from WASp/ or wild-type (WT) mice, and 5  106 BM cells were
transplanted intravenously into sublethally irradiated (500 cGy) MT
recipient mice.
Reagents and antibodies
Reagents used in this study include PyroninY and 4,6-diamidino-
phenylindole:2HCl (DAPI) from Invitrogen (Carlsbad, CA). Antimurine
antibodies included CD24, CD21, B220, CD5, CD43, and CD1d from BD
Biosciences PharMingen (San Diego, CA), BP1 from eBioscience (San
Diego, CA), CD23 from Invitrogen, IgM from Southern Biotechnology
Associates (Birmingham, AL), and CD19 from BioLegend (San Diego,
CA). Antihuman antibodies included CD24, CD38, and IgD from BD
Biosciences PharMingen, CD19 from BioLegend, and IgM from Southern
Biotechnology Associates. Purified polyclonal rabbit anti-WASp antibody
was a kind gift from Dr H. Ochs (University of Washington, Seattle, WA).
Cy5 antirabbit polyclonal IgG was purchased from Jackson ImmunoRe-
search Laboratories (West Grove, PA).
Flow cytometry
Single cell suspensions were incubated with fluorescently labeled antibod-
ies for 20 minutes at 4°C. Data were collected on a FACSCalibur or LSR II
flow cytometer (BD Biosciences, San Jose, CA) and analyzed using FlowJo
software (TreeStar, Ashland, OR). For cell-cycle analysis, cells were
surface stained, fixed overnight with 2% paraformaldehyde, washed, and
incubated for 30 minutes with 1 g/mL of DAPI in phosphate-buffered
saline with 0.1% fetal calf serum and 0.1% Triton X-100. A total of
1.5 g/mL of PyroninY was added immediately before analysis. Intracellu-
lar WASp staining was performed according to instructions for the BD
Biosciences PharMingen Fixation/Permeabilization Solution Kit. Absolute
cell numbers were determined using a Neubauer Chamber and calculated
based on relative percentages obtained from fluorescence-activated cell
sorter (FACS) analysis.
Bromodeoxyuridine incorporation
Mice were fed with bromodeoxyuridine (BrdU) continuously via the
drinking water (1 g/mL BrdU, Sigma-Aldrich, St Louis, MO; and 10%
sucrose) and killed at indicated time points. Cells from BM, spleen, and
peritoneal cavity were surface stained, then fixed and permeabilized,
treated with DNase, and stained with anti-BrdU FITC (BrdU Kit from
BD Biosciences).
Immunologic synapse analysis
Lipid bilayers with or without glycosylphosphatidylinositol-linked intercel-
lular adhesion molecule-1 (ICAM-1) were prepared by liposome spreading
as previously described.20 Briefly, Alexa 633-streptavidin was incorporated
into the bilayers and used to load anti-BCR at a density of 150 molecules/
m2, and Alexa532-labeled glycosylphosphatidylinositol-linked ICAM-1
was either added or not at 80 molecules/m2. B cells were settled on lipid
bilayers, and differential interference contrast images of several indepen-
dent areas were taken after 20 minutes. Central supramolecular activa-
tion cluster (cSMAC) frequency was determined by counting B cells
aggregating anti-BCR and forming a cSMAC as a percentage of total
B cells. Immunologic synapse (IS) frequency reflects B cells forming
cSMACs and pSMACS as a percentage of all B cells forming cSMACs.
The B-cell contact area was quantified by interference reflection
microscopy (IRM) as described.21
Human peripheral blood
Peripheral blood was collected from a WAS patient and healthy persons
after informed consent was obtained in accordance with the Declaration of
Helsinki and the Institutional Review Board guidelines of the Children’s
Hospital and Regional Medical Center (Seattle, WA). Peripheral blood
mononuclear cells were isolated using Ficoll-Hypaque (GE Healthcare,
Little Chalfont, United Kingdom) gradient centrifugation.
Results
Specific defects in mature B-cell subsets in WASp/ mice
WASp/ mice were described almost a decade ago.12,13 Whereas a
recent report has demonstrated a reduction in splenic MZ B-cell
numbers,8 to date, only relatively limited analysis of various B-cell
compartments in WASp/ mice has been performed. We therefore
evaluated each of the B-cell developmental populations within the
BM, spleen, and peritoneal cavity in WT versus WASp/ mice.
We first analyzed central B-cell development within the BM
according to Hardy’s classification22 (Figure S3A, available on the
Blood website; see the Supplemental Materials link at the top of the
online article). No significant differences were observed in the pro
B-cell to immature B-cell stages (fractions A-E; Figures 1A, S1A).
In contrast, both the absolute and relative number of recirculating,
IgD B cells (fraction F) were consistently reduced ( 1.8-fold) in
WASp/ mice (Figures 1A, S1A).
Immature B cells emigrate from the BM to the spleen as
transitional B cells (transitional 1 [T1] and 2 [T2]) where, in
response to microenvironmental cues, they differentiate into either
follicular mature (FM) B cells, or marginal zone precursor (MZP)
and MZ B cells. As shown in Figure 1B, T1 cells are CD21lowCD24hi,
T2 cells CD21intCD24hi, and FM B cells are CD21intCD24int.
CD21hiCD24hi MZP/MZ B cells can be further distinguished by
CD23: MZP are CD23hi, whereas MZ B cells are CD23low. Total
B-cell numbers, as well as the absolute number of FM B cells, were
comparable between WT and WASp/ mice (Figure 1B,C).
However, we observed a significant increase in relative and
absolute numbers of T1 B cells ( 1.5-fold, Figures 1B,C, S1B,C).
In addition and consistent with previous studies,8 MZP and MZ
B-cell numbers were reduced 3-fold. In addition, cells with a
CD21hiCD1dhi phenotype, independent markers for the MZ lin-
eage, were similarly reduced (Figure 1B).
Next, we analyzed B1 cells in the peritoneal cavity that are
crucial for TI immune responses. They can be further separated by
CD5 into B1a (CD5hi) and B1b (CD5low) cells. Our analysis
identified a relative increase in B1b cells (not shown) that reflected
a relative and an absolute decrease in the number of B1a cells
(Figure 1D,E;  2-fold reduction). We also determined the fre-
quency of BM B1 cell precursors23 and found no differences
(Figure S1D).
We conclude from this analysis that WASp deficiency does not
affect early BM B-cell development but significantly impacts
specific B-cell developmental subpopulations in the spleen and
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peritoneal cavity and leads to a reduction of the number of
recirculating B cells within the BM.
B-cell defects in WASp/ mice are B-cell intrinsic
To directly determine whether the observed B-cell phenotype,
including the loss of MZ B cells in WASp/ mice, is the result of a
B cell–intrinsic defect, we carried out a series of transplantation
experiments using B cell–deficient, MT-recipient animals. Suble-
thally irradiated MT mice (500 cGy) were transplanted with BM
cells from WASp/ or littermate control mice. Analysis of
peripheral blood at 5.5 weeks after transplantation showed a
significant increase in the percentage of circulating T1 B cells and a
parallel reduction in mature B cells in recipients of WASp/ BM
(Figure 2B; of note, MZP/MZ B cells are not present in peripheral
blood). Six weeks after transplantation, recipient mice were killed
and B-cell subsets in BM, spleen, or peritoneal cavity were
analyzed by FACS. Notably, in recipients of WASp/ marrow, all
peripheral B lineage cells, but less than 10% of splenic T cells,
were donor derived as assessed using intracellular WASp staining
(not depicted). We observed no significant differences in either
absolute number or relative composition of early to immature BM
B lineage cells (fractions A-E). However, as in WASp/ mice,
there was an approximately 2-fold decrease in recirculating IgD
BM B cells (fraction F, Figures 2A, S2A). In addition, the absolute
number of splenic B cells was significantly reduced, and this
change was reflected by a reduction in both T2 ( 2-fold) and
MZP/MZ B cells (each 3-fold; Figure 2C). The percentage of T1
B cells was significantly increased, although this change was not
Figure 1. The B-cell phenotype in WASp-deficient
mice. (A) BM was stained for expression of B220, CD43,
IgM, BP1, CD24, CD19, and IgD and developmental
stages determined according to the Hardy classification.
Absolute numbers for each fraction (Fr) A through F are
shown in WT versus WASp/ mice (ko) (n  12).
(B,C) Splenocytes were stained for expression of B220,
CD19, CD24, CD21, CD23, and CD1d and B-cell subsets
analyzed. (B) Representative FACS blot gated on
B220CD19 cells in a WT versus WASp/ mouse.
(C) Absolute numbers of splenic B-cell subsets from WT
versus WASp/ mice (n  12). (D,E) Peritoneal B cells
were stained for IgM, CD5, and Mac1. (D) Representa-
tive FACS blot of gating B1 cells in a WT and a WASp/
mouse. (E) Absolute numbers of B1, B1a, and B1b cells
in WT (n  8) versus WASp/ mice (n  7).
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reflected in absolute T1 B-cell numbers (Figures 2C, S2B).
Analysis of peritoneal B cells showed a decrease in the absolute
number of B1a B cells consistent with the finding in WASp/ mice
(Figure 2D). These combined data demonstrate that each of the
changes in the B-cell compartment in WASp/ mice reflects a
B cell–intrinsic defect.
The relative level of WASp expression mirrors its functional
requirement in B-cell subsets
We next asked whether the observed B-cell phenotype correlates
with the relative level of WASp expression. BM, splenic, and
peritoneal B cells were stained intracellularly with an antibody
specific for WASp in addition to the previously mentioned cell
surface markers. In the BM, expression of WASp was similar in
fractions A to E but increased significantly in recirculating IgD
B cells (fraction F; Figure 3A). Within the spleen, expression of
WASp was highest in MZP and MZ B cells (Figure 3B), whereas in
the peritoneal cavity, B1a cells expressed the highest levels of
WASp (Figure 3C). These results suggest that those B-cell subsets
that normally express higher levels of WASp are more sensitive to
WASp deficiency.
WASp B cells exhibit a selective advantage beginning at the
late transitional stage
We next analyzed intracellular WASp expression within B-cell
subsets isolated from WASp/ female mice. This approach allowed us
Figure 2. The WASp-deficient B-cell phenotype is B cell–intrinsic. BM from WT or WASp/ mice was transplanted into sublethally irradiated MT mice. Recipient mice
were killed 6 weeks after transplantation, and B-cell subsets in BM, spleen, and peritoneal cavity were analyzed. Shown are absolute numbers for (A) BM (n  9 recipient
mice), (C) spleen (n  7), and (D) peritoneal cavity (n  7) and the relative percentage of subsets in (B) peripheral blood (n  12).
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to identify developmental stages at which WASp B cells might
manifest a selective advantage. We observed little or no evidence of
selective advantage for WASp B cells during BM development:
approximately 55% of cells within each of the BM fractions A, B, D,
and E expressed WASp (Figures 4A, S3C). Interestingly, we observed a
specific reduction in WASp cells in BM fraction C (only  33% of
fraction C were WASp). However, analysis in WT mice also showed
reduced expression of WASp specific to fraction C (only  40%
WASp; Figure S3B). This change probably reflects an artifact second-
ary to the rapid proliferation of fraction C pre-B cells.
In contrast to BM B-cell development, the percentage of
WASp B cells increased progressively within the peripheral
B-cell compartment. This change was first evident within T2
B cells and was most prominent in MZP/MZ B cells: Whereas only
approximately 55% of T1 B cells were WASp, 65% of T2 and FM
B cells and more than 85% of MZP/MZ B cells were WASp
(Figure 4A-C). In addition, approximately 70% of recirculating
IgD B cells in the BM (fraction F) expressed WASp. Within the
B1 B-cell compartment, the majority of cells expressed WASp with
the greatest skewing present within B1a cells: approximately 80%
of B1a cells were WASp compared with approximately 70% of
B1b cells (Figure 4D,E).
These combined observations suggest that there is little or no
selective advantage for WASp B cells in early B-cell develop-
ment, and clearly demonstrate selective advantage for WASp cells
within the peripheral B-cell compartment beginning at the T2
B-cell stage.
WASp deficiency primarily impacts peripheral B-cell homeostasis
The results described so far suggest that WASp/ B cells manifest
either a survival/homeostatic defect or a specific developmental
defect(s) leading, ultimately, to severely reduced numbers of
mature MZ, B1a, and recirculating naive B cells.
Notch signaling plays a crucial role in MZ B-cell develop-
ment.24 Because this subset is most severely affected in WASp/
mice, we determined the expression of the Notch target genes,
Hes1 and Deltex1,25 in FM and MZ B cells from WT versus
WASp/ mice. Hes1, but not Deltex1, expression levels were
consistently reduced in WASp/ B cells suggestive of a partial
defect in Notch2 signaling (Figure S4). However, when we
determined Hes1 expression in FM and MZ B cells derived from
chimeric BM transplantation recipients, no differences were ob-
served (Figure S4A,B), indicating that the alteration in Hes1 levels
in WASp/ mice does not reflect a B cell–intrinsic defect.
To directly differentiate between a survival/homeostatic versus a
developmental defect, we performed in vivo BrdU labeling experi-
ments. BrdU is incorporated into dividing cells during S phase of the cell
cycle. Therefore, if a developmental defect were to account for the
observed phenotype, we hypothesized that fewer BrdU-labeled mature
B cells would be present in WASp/ mice (as there would be fewer
newly formed, recently divided cells). In contrast, if this phenotype
reflected an alteration in B-cell homeostasis, turnover rates would be
predicted to be higher, resulting in equal or increased numbers of BrdU
cells in WASp/ versus WT mice.
Experimental animals fed BrdU via the drinking water were
killed at day 3 or 7 and B cells analyzed for BrdU incorporation. As
expected (based on the lack of evidence for an early BM
developmental defect), BrdU labeling was similar in early BM
stages (fractions A-E) and only slightly increased in T1 and T2
B cells (day 3; Figure 5A; data not shown). In contrast, a
significantly greater fraction of splenic FM, MZP, and MZ B cells
Figure 3. Relative WASp expression levels in distinct
B-cell subsets. B cells in different lymphoid compart-
ments from a WT mouse were stained for WASp expres-
sion in addition to surface markers to determine B-cell
subpopulations. Relative WASp expression and mean
fluorescent intensity are shown for each of the B-cell
subsets derived from (A) BM, (B) spleen, and (C) perito-
neal cavity. Data shown are representative of more than
5 individual mice.
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were BrdU in WASp/ mice (Figure 5A). In addition, recirculat-
ing B cells exhibited faster labeling on days 3 and 7, respectively
(Figure 5A; data not shown). B1a and B1b populations exhibited
significantly more BrdU cells on day 3 and a trend for greater
labeling at day 7 (Figure 5B). Comparing the BrdU labeling
kinetics, it was evident that the turnover rate of WASp/ B cells
was significantly higher beyond the T1 B-cell stage. Notably, the
absolute number of MZ B cells that incorporated BrdU was similar
in both strains (Figure 5C), supporting the conclusion that the
overall reduction in MZ B-cell numbers in WASp/ mice was
Figure 4. WASpB cells exhibit a selective advantage beginning at the late transitional B-cell stage. Expression of WASp was determined in B-cell subsets derived from
BM, spleen, and peritoneal cavity in female WASp heterozygous mice. Representative example of staining in (A) BM, (B) spleen, and (D) peritoneal cavity. Percentage of
WASp-positive B cells in each subset in (C) spleen (n  8) and (E) peritoneal cavity (n  6).
WASp IS ESSENTIAL FOR PERIPHERAL B-CELL HOMEOSTASIS 4163BLOOD, 15 NOVEMBER 2008  VOLUME 112, NUMBER 10
 For personal use only. by FREDERIC BARON on January 26, 2012. bloodjournal.hematologylibrary.orgFrom 
unlikely to be due to a developmental defect. We also performed
pulse-chase studies, by feeding BrdU for 7 days followed by
analysis of splenic B cells on days 7 and 14 after labeling. As
expected, BrdU FM and MZP/MZ B cells turned over signifi-
cantly more rapidly in WASp/ mice (Figure S5A). Consistent
with a higher turnover rate in each of the mature B-cell subsets, a
significantly greater percentage of all peripheral B cells had entered
cell cycle in WASp/ mice (S and G2/M phase, Figure 5D).
Survival of mature resting B cells in the periphery depends on
coordinate signals mediated via the BCR and B-cell activating
factor of the TNF family receptor (BAFF-R). We used several
approaches to determine whether defects in survival signaling
Figure 5. B cells in WASp-deficient mice exhibit a higher turnover rate. (A-C) WT and WASp/ mice were continuously fed BrdU via the drinking water for up to 7 days.
Mice were killed on day 3 or 7 and splenocytes stained for BrdU in addition to surface makers to identify B-cell subsets. Percentage of BrdU cells in (A) splenic and
(B) peritoneal B-cell subsets. (C) Absolute numbers of BrdU MZ B cells in WT versus WASp/ mice. Data shown reflect the average of 3 mice per time point and are
representative of 2 independent experiments. *P  .05. (D) For cell-cycle analysis, splenocytes from WT or WASp/ mice were stained with PyroninY and DAPI in addition to
surface markers. Data show the percentage of cells in either S- or G2/M phase of the cell cycle (average of 3 mice) from one of 3 independent experiments. *P  .05; **P  .01.
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might account for altered homeostasis of WASp/ B cells.
A previous report suggested that lower expression of the prosur-
vival protein, Bcl-2, correlated with increased apoptosis in WASp/
human B cells.26 We observed no difference in Bcl-2 expression in
B-cell subsets from WT versus WASp/ mice (Figure S5B). We
also observed no differences in cell survival in response to BCR
engagement in FACS-sorted WT versus WASp/ T1 or FM
B cells; or in survival of unstimulated or BAFF-treated T1, T2, FM,
or MZP/MZ B cells (measured at 24 hours; Figure S5C). BAFF-R
engagement promotes processing of NF-B2 p100 and enhances
the expression of survival genes. We observed similar BAFF-R
levels in WT and WASp/ B cells and similar processing of p100
to p52 after BAFF stimulation (Figure S5D,E). Akt plays a key role
in B-cell survival and is up-regulated in MZ B cells.27,28
A comparison of p-AKT basally or after BCR engagement in each
peripheral B-cell subset identified no differences between WT and
WASp/ cells (Figure S5F). We conclude that alterations in B-cell
homeostasis in WASp/ mice are largely independent of B cell–
intrinsic survival signals mediated via the BCR and BAFF-R.
Because integrins play an important role in the positioning of
MZ B cells,29 we investigated whether the observed phenotype of
WASp/ mice could be explained by an underlying defect in their
ability to activate integrins. The formation of the mature IS after
BCR stimulation requires the inside-out activation of integrins and
is characterized by the segregation of leukocyte function-
associated antigen-1 (LFA-1) into a stable peripheral supramolecu-
lar adhesion complex (pSMAC). Therefore, we compared the
formation of the mature IS in WT and WASp/ B cells after
settling on planar lipid bilayers containing anti-BCR with or
without ICAM-1. We observed that WT and WASp/ B cells were
able to aggregate activating antibody into a cSMAC to a similar
extent, both in the presence and absence of ICAM-1 (Figure 6A,B).
However, in the presence of ICAM-1, WT B cells exhibited an
increased contact area, shown by IRM, as a result of forming a
stable pSMAC (Figure 6A,D). In contrast, WASp/ B cells were
unable to increase their contact area in the presence of ICAM-1 and
were significantly impaired in the formation of the mature IS as a
result of their inability to aggregate LFA-1 into a stable pSMAC
(Figure 6A,C-E). These findings indicate that WASp/ B cells
exhibit defective BCR-mediated inside-out integrin signaling. This
impairment in integrin function could give rise to inadequate
retention and/or positioning of MZ B cells and may explain the
decreased MZ B-cell population.
WASp human B cells exhibit a selective advantage in vivo
To begin to determine whether our observations in this murine
model were relevant to human B-cell homeostasis, we initially
analyzed WASp expression in peripheral B-cell subsets derived
from healthy persons. As described previously, immature/
transitional, naive-mature, and IgM memory B cells can be
identified by relative staining for CD38, CD24, CD10, and IgM in
human peripheral blood30 (Figure 7A). Using these markers in
association with intracellular WASp staining, we analyzed expres-
sion of WASp in human peripheral B-cell subsets. Consistent with
work suggesting that IgM memory B cells represent the func-
tional equivalent of murine MZ B cells,31 this population exhibited
a significantly higher level of WASp expression in comparison with
either transitional or mature, naive human B cells (Figure 7B).
We also analyzed the percentage of WASp B cells within a
WAS patient with a revertant mutation affecting a common
lymphoid progenitor.32 This patient, similar to other older WAS
patients, exhibited marked lymphopenia with only approximately
1% B cells present in his peripheral blood. However, we readily
observed a significant increase in the relative number of circulating
WASp B cells with maturation: within immature B cells, less than
1% expressed WASp, and this percentage increased in mature
B cells and was highest in memory B cells (Figure 7C,D). This
result strongly suggests that, consistent with our results in mice,
WASp expression leads to a selective advantage for mature
peripheral B-cell stages in humans.
Discussion
WASp is expressed in all nonerythroid derived hematopoietic
lineages, including B, T, and NK cells, as well as dendritic cells,
neutrophils, and other myeloid-derived populations. These cell
populations function in concert in an interactive network to
mediate both innate and adaptive immune responses. Thus, to
understand the contribution of a specific cell lineage to the clinical
phenotype in WAS, it is crucial to use models capable of
identifying cell intrinsic functional responses.
Figure 6. WASp is required for integrin activation and
pSMAC formation at the B-cell immunologic syn-
apse. WT and WASp/ B cells were settled onto lipid
bilayers containing anti-kappa antibody (green) or anti-
kappa and Alexa532-conjugated ICAM-1 (red) and im-
aged by confocal microscopy after 20 minutes of inter-
action. (A) Differential interference contrast (DIC),
fluorescence and interference reflection microscopy (IRM)
images of representative cells are shown. Quantification
of the percentage of B cells forming (B) a cSMAC or
(C) an IS (cSMAC  pSMAC) and (D,E) the area of
B-cell contact with the bilayer. For each condition, a
total of 20 to 50 B cells were analyzed. Bars represent
mean values plus or minus SEM. Data are representa-
tive of 2 independent experiments. Scale bar repre-
sents 2.5 m. ***P  .001.
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In the current study, we analyzed the phenotype of key
B lymphoid compartments within WASp/ mice. Our data
demonstrate that central BM B-cell development is normal in
WASp/ mice. In contrast, the mature, peripheral B-cell compart-
ment exhibits marked alterations with a reduction in the absolute
numbers of splenic MZP/MZ B cells, peritoneal B1a B cells, and
BM-derived recirculating mature B cells. Using chimeric BM
transplantation experiments, we show that each of these changes is
secondary to a B cell–intrinsic defect(s). Further, we show a strong
correlation between the observed B-cell defects and relative level
of WASp expression in populations most severely affected in
WASp/ mice. Consistent with each of these findings, we observe
Figure 7. WASp mature B cells exhibit a selective
advantage in humans. (A,B) Expression of WASp in
immature, mature, and IgM memory B cells in peripheral
blood from a healthy person. Peripheral blood mono-
nuclear cells from a healthy person were stained for
CD19, CD24, CD38, CD10, CD27, and IgM in addition to
WASp. (A) Based on these markers, the following B-cell
subsets were identified: CD19CD24hiCD38hi immature/
transitional B cells, CD19CD24lowCD38int naive mature
B cells, and CD19CD24hiCD38lowIgM IgM memory
B cells. Transitional B cells express high levels of CD10,
whereas memory B cells express high levels of CD27.
(B) WASp expression and relative mean fluorescent
intensity are shown for each of these B-cell subsets.
Data shown are representative of more than 3 healthy
persons. (C,D) Analysis of B cells in a WAS patient with
a revertant mutation. B-cell subsets and relative WASp
expression were determined in a WAS patient with a
known revertant mutation. (C) B-cell subsets were
identified as described for panel A. (D) WASp expres-
sion in immature, mature, and memory B cells (gated
as in panel A) from the WAS patient.
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a selective advantage for WASp B cells beyond the early
transitional (T1) B-cell stage. Our analysis further suggests that
this phenotype is caused by a homeostatic defect. Finally,
analysis of peripheral blood from normal persons and a WAS
patient with a revertant mutation indicates that key observations
derived from the murine knockout model mirror the role for
WASp in human B-cell function.
Our data complement and extend previously published re-
sults12,13 suggesting that WASp expression was largely dispensable
for early B-cell development. We observe no difference in the
number or phenotype of BM B-cell developmental subsets or early
transitional (T1) B cells in the spleen in WASp/ versus WT mice;
or in chimeric MT recipient mice transplanted with WT versus
WASp/ BM cells. In addition and consistent with this, there was
no selective advantage of WASp B cells at these developmental
stages in WASp heterozygous mice. In contrast to our findings, a
previous study suggested that WASp BM cells exhibit a selective
advantage in transplantation models because of defective chemo-
taxis in WASp/ cells.33 Whereas this difference may reflect
alternative methods for transplant conditioning, our analysis of
WASp heterozygous mice has failed to identify any significant
selective advantage for lineage-negative, hematopoietic stem
cells or BM derived myeloid cells32 (A. Astrakhan and D.J.R.,
unpublished results, 2008).
We show that WASp expression increases after the early
transitional B-cell stage to reach its highest expression level in
MZP, MZ, and B1a B cells. This increase in WASp expression is
associated with a progressive selective advantage of WASp over
WASp B cells and a decrease in cell numbers from the late
transitional stage to the MZ B-cell compartment. This selective
advantage is most evident in experiments analyzing B-cell intrinsic
function: recipients of WASp/ BM exhibited significantly fewer
T2, MZP, and MZ B cells resulting in absolute reduction in the total
number of splenic B cells. In contrast, WASp/ mice exhibit a
specific deficit in splenic MZP and MZ B cells, whereas the number
of T2 cells is normal and the number of T1 B cells is modestly
increased. This latter difference might reflect a B-cell extrinsic
effect. Whereas we used young mice (6-8 weeks old) for all
experiments, we cannot exclude that subclinical inflammatory
processes might influence the B-cell phenotype in the WASp/
mouse model. In contrast, such factors are largely excluded in the
transplant experiments because very few non-B cells are WASp-
deficient in this model. Notably, whereas the absolute number of
splenic FM B cells was normal in both WASp/ mice and in our
chimeric transplantation model, we readily observed reductions in
mature recirculating B-cell numbers in the BM in both models.
This suggests that, whereas ongoing homeostatic signals may be
sufficient to maintain splenic FM B-cell numbers (as discussed in
greater detail later in “Discussion”), BM recirculating B cells and
naive B cells in other lymphoid compartments are probably more
sensitive to cell loss.
The peritoneal B1 cell compartment was previously described
as unaltered in WASp/ mice.12 In contrast, whereas there was no
difference in B1 progenitors in the BM, we observed a significant
decrease in both percentage and absolute number of B1a cells; and
a strong selective advantage for WASp-expressing B1a and B1b
cells. B1a B cells are crucial for protection against S pneumonia.34
Thus, the increased susceptibility of WAS patients to encapsulated
bacteria, which has also been described in WASp/ mice,35 may
be largely explained by the reduced number of both MZ and B1a
B cells. Consistent with these data, a recent study also demon-
strated altered TI-type 2 immune responses in this strain.8
Importantly, several key features of our analysis were similar in
both murine and human B cells. WASp expression was increased in
mature versus immature/transitional human B cells and was highest
in IgM memory B cells, the functional, and possibly developmen-
tal, equivalent of murine MZ B cells.31 Moreover, analyzing blood
from a WAS patient with a revertant mutation, we observed a
proportional increase in WASp cells in mature versus transitional
B cells and further enrichment within the memory B-cell compart-
ment, findings consistent with a selective advantage for WASp
follicular mature and memory B cells. Although we were unable
to identify an enrichment of WASp B cells within the IgM
memory compartment, the very low absolute numbers of total
and IgM memory B cells significantly limited this analysis. It
is also possible that WASp human IgM memory B cells are
preferentially localized to lymphoid compartments not available
in our analysis.
Overall, our phenotypic data in humans and mice are in accord
with previous studies in WAS: the number of total B cells and MZ
B cells are decreased in both human WAS patients and WASp/
mice4,8,13,19; and similar to our observations in mice, a previous
study also suggests that the relative percentage of immature
peripheral B cells is increased in WAS patients.36
Our data clearly define the late transitional stage as the point at
which WASp expression becomes crucial for B-cell function. We
also addressed the critical question as to whether this reflects a
developmental versus homeostatic defect. We excluded that im-
paired Notch signaling is the major reason for a diminished MZ
B-cell compartment. Using in vivo BrdU labeling, we demonstrate
significantly higher BrdU incorporation in splenic B-cell subsets,
recirculating BM B cells, as well as B1 B cells, findings consistent
with a higher turnover rate for each of these subpopulations.
Notably, the absolute number of BrdU MZ B cells was equal or
even slightly higher in WASp/ versus WT mice. This latter
finding essentially excludes a developmental defect because the
number of newly generated MZ B cells is comparable. Moreover,
cell-cycle analysis revealed an increase in cycling cells (S- and
G2/M-phase) in nearly all peripheral B-cell subsets in WASp/
mice. This feature was most pronounced in T2 B cells, the subset
that is most highly responsive to homeostatic signals.25 These
coordinate findings suggest that an increase in newly generated
B cells can partially compensate for homeostatic cell losses that
occur in WASp/ mice. Such compensation appears most efficient
within the FM B-cell pool as overall FM B-cell numbers are not
significantly reduced in WASp/ mice.
Having excluded a developmental defect, we also tested
whether key B cell–intrinsic survival signals might be selectively
impaired in WASp/ mice. Previous reports have suggested an
increased rate of spontaneous apoptosis in human B cells derived
from peripheral blood of WAS patients.26,37 However, conclusions
from these and other studies using B cells from WASp/ mice are
difficult to interpret because nearly all were performed using
heterogeneous populations or cell lines. BCR and BAFF-R signals
coordinately provide the crucial homeostatic and survival signals
for late transitional and mature B cells.38 Therefore, we tested both
basal and/or receptor-mediated survival signals using highly puri-
fied, WT versus WASp/ B-cell subsets. We were unable to
identify any alterations in basal or receptor-triggered signals,
including no differences in: relative receptor expression, cell
survival, antiapoptotic signaling, Akt activation, or p100 processing.
The absence of a survival defect in WASp/ B cells suggests
that alternative defects in homeostasis probably account for the
observed losses within the mature B-cell compartment. A previous
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study has shown a requirement for Pyk-2 driven, chemokine
responses in MZ B-cell development,39 and recent work has
identified defects in chemokine-driven WASp/ B-cell migra-
tion.18 However, because the initial pool of both MZ precursor and
mature MZ B cells is intact in WASp/ mice, altered migration
alone seems doubtful to explain the selective loss of these subsets.
Instead, we predict that signals that promote retention of MZP/MZ
B cells within the MZ niche are probably deficient in WASp/
animals. MZ B-cell localization requires up-regulation of LFA-1
and 	4
1 integrins as well as signaling via Sphingosine-1-
phosphate (S1P) receptors.29,40-42 Transcript levels for S1P3, but not
S1P1, were significantly decreased in MZ B cells from WASp/
mice (Figure S4). However, because S1P3-deficient mice exhibit
normal MZ B-cell numbers,41,42 this observation alone cannot
explain MZ B cell losses. In addition, WASp/ MZ B cells express
normal levels of LFA-1 and CD62L (data not shown) and show
comparable ICAM-1 and VCAM-1 binding.8
Integrin signals are crucial for the retention of B cells within the
MZ.29 Further, integrin binding can be directly influenced by BCR
signaling, and such changes are probably important in regulating
the MZ B-cell compartment. Using lipid bilayers, we show that
WASp/ B cells are able to aggregate antigen into cSMACs after
receptor stimulation. However, WASp/ B cells exhibit a near-
complete deficit in integrin clustering in response to BCR and
ICAM costimulation, as demonstrated by the failure to generate a
stable pSMAC or to increase the cell:lipid bilayer contact area.
BCR-driven signals promote a change from a low to high avidity
integrin binding state, thereby enhancing B-cell adherence to local
adhesion molecules.43 We hypothesize that the deficit in inside-out
signaling shown herein limits retention of WASp/ MZ B cells
and thereby promotes MZ B-cell loss via reduced access to
microenvironmental survival signals. This retention deficit prob-
ably also impacts additional WASp/ mature B-cell subsets. Thus,
our combined data best support a model in which inefficient
localization of B cells within key niches leads to an ongoing
homeostatic defect. Direct measurement of integrin affinity in
resting versus stimulated MZ B cells, as well as studies of in vivo
positioning, are required to fully address this question.
In conclusion, the current study precisely defines the B-cell
intrinsic defects in WASp deficiency. This work sets the stage for a
better understanding of the clinical phenotype of WAS and
provides new insight into the regulation of the mature peripheral
B-cell compartment. In addition, we show, for the first time, that
WASp human and murine B cells exhibit a strong selective
advantage. These observations suggest that future gene therapy
strategies, leading to sustained endogenous levels of WASp expres-
sion in B lineage cells, might rescue these homeostatic defects and
promote improved humoral immunity in WAS.
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